testosterone pellet

Phase 3Small molecule

UUniversity of Sao Paulo General Hospital

testosterone pellet is one of 4 small molecule programs targeting Menopause. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MenopauseRecruiting

MenopausePhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Menopause

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

5 2

Orilissa

Veozah

2 4

testosterone pellet

UUniversity of Sao Paulo General Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Menopause

NCT06343870

Clinical

Trials by Indication[1]

Menopause1 trial

Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)

Recruiting·UUniversity of Sao Paulo General Hospital·Phase 3·NCT06343870·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for testosterone pellet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — testosterone pellet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for testosterone pellet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Sao Paulo General Hospital

testosterone pellet

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Menopause1 trial

References

Drug Info

Quick Facts

Related News